Key result
Propranolol therapy in coronary artery disease patients significantly reduced arachidonate-induced platelet TXA2 generation in vitro compared to those not taking it (21 vs 725 pg, p<0.001).
Why the study?
Does propranolol therapy reduce platelet release and prostaglandin generation in patients with coronary heart disease?
Population
29 patients with coronary disease (15 not taking propranolol, 14 taking propranolol) and 15 normal subjects
Comparison
Propranolol therapy vs No propranolol therapy and normal subjects
Design
Cross-sectional
Authors
Loading...
May indicate antiplatelet effects of propranolol in CAD; hypothesis-generating and should not yet change practice.
Cross-Sectional (n=44)
Does propranolol therapy reduce platelet release and prostaglandin generation in patients with coronary heart disease?
Absolute Event Rate: 21% vs 725%
p-value: p=<0.001
Propranolol therapy significantly reduces the capability of platelets to generate TXA2 in vitro, suggesting a potential mechanism for its beneficial effects in coronary artery disease.
Mehta et al. (1982) conducted a cross-sectional in Coronary heart disease (n=44). Propranolol therapy vs. No propranolol therapy was evaluated on Arachidonate-induced platelet TXA2 generation in vitro (pg TXB2/10^8 platelets) (p=<0.001). Propranolol therapy in coronary artery disease patients significantly reduced arachidonate-induced platelet TXA2 generation in vitro compared to those not taking it (21 vs 725 pg, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: